The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks (RICMO-ASCVD) A Prospective, Blinded Endpoint, Multi-center, Cohort Study

What this Trial Is About

Researchers are studying atherosclerotic cardiovascular disease (ASCVD), a group of disorders caused by atherosclerosis that mainly affect the heart, brain, kidneys, and other arteries, leading to artery blockages. This condition has the highest rates of illness and death worldwide, especially in patients with very high-risk ASCVD who face a greater chance of recurrence. The study evaluates the long-term protective effects of remote ischemic conditioning (RIC) on major organs in this high-risk group through a prospective, multicenter cohort study with blinded outcome assessment. The study compares two groups: one group will receive RIC treatment involving 5 cycles of cuff inflation for 5 minutes and deflation for 5 minutes on both upper limbs at 200 mmHg, twice daily for one year, alongside guideline-based treatment. The other group will receive only guideline-based treatment without RIC. RIC is being assessed as an additional therapy to protect the heart, brain, and kidneys and prevent ASCVD event recurrence. Participants will be monitored over one year, with researchers tracking the incidence of composite endpoint events such as cardiovascular events, strokes, kidney function changes, blood pressure, blood glucose, blood lipids, new diabetes onset, vascular death, and overall mortality. Assessments include serological tests and functional scores like the Barthel Index. Safety and outcomes will be observed during this period to understand the effects of long-term RIC in very high-risk ASCVD patients.

The Long-term Effect of Remote Ischemic Conditioning on Main Organs in ASVCD Patients With Very High Risks